Estropipate Pregnancy and Breastfeeding Warnings

Brand names: Ogen, Ogen 0.625, Ogen 1.25, Ogen 2.5, Ortho-Est

Medically reviewed by Drugs.com. Last updated on Aug 4, 2023.

Estropipate Pregnancy Warnings

There appears to be little or no increased risk of birth defects in children born to women who have used estrogens from oral contraceptives inadvertently during early pregnancy. There are no controlled data in human pregnancy.

AU TGA pregnancy category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have not shown evidence of an increased occurrence of fetal damage.

US FDA pregnancy category X: Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

Contraindicated

AU TGA pregnancy category: B1
US FDA pregnancy category: X

Comments:
-If pregnancy occurs, discontinue treatment immediately; there is no indication for use during pregnancy.

See references

Estropipate Breastfeeding Warnings

Use caution

Excreted into human milk: Yes

Comments:
-Estrogen use during lactation has been shown to decrease the quantity and quality of breast milk.
-Detectable amounts of estrogens have been found in breast milk.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer